These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 26112941)

  • 1. Cytotoxic activity of immune cells following administration of xenogeneic cancer vaccine in mice with melanoma B-16.
    Fedosova NI; Voeykova IM; Karaman ОМ; Symchych TV; Didenko GV; Lisovenko GS; Evstratieva LМ; Potebnia GP
    Exp Oncol; 2015 Jun; 37(2):130-4. PubMed ID: 26112941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of xenogeneic vaccine modified with embryonal nervous tissue antigens in the treatment of B16-melanoma-bearing mice.
    Voeykova IM; Fedosova NI; Karaman OM; Yudina OY; Didenko GV; Lisovenko GS; Evstratieva LM; Potebnya GP
    Exp Oncol; 2014 Mar; 36(1):24-8. PubMed ID: 24691280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
    Hawkins WG; Gold JS; Dyall R; Wolchok JD; Hoos A; Bowne WB; Srinivasan R; Houghton AN; Lewis JJ
    Surgery; 2000 Aug; 128(2):273-80. PubMed ID: 10923004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental study of the efficacy of combined use of cancer vaccine and interferon.
    Potebnya GP; Kudryavets YY; Lisovenko GS; Cheremshenko NL; Voeykova IM; Trokhimenko NV; Symchich TV; Evstrateyva LM
    Exp Oncol; 2007 Jun; 29(2):102-5. PubMed ID: 17704740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Wei Y; Kan B
    Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):118-21. PubMed ID: 11783014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary observation on antitumor effect of HPV58 composite DNA vaccine].
    Wang H; Yu JY; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):523-7. PubMed ID: 24284225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer effect and immunologic response to xenogeneic embryonic proteins in mice bearing Ehrlich solid carcinoma.
    Symchych TV; Fedosova NI; Karaman ОМ; Yevstratieva LM; Potebnia HP
    Exp Oncol; 2017 Mar; 39(1):42-48. PubMed ID: 28361853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
    Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
    Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
    Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound-responsive and mannose-modified gene carrier.
    Un K; Kawakami S; Suzuki R; Maruyama K; Yamashita F; Hashida M
    Mol Pharm; 2011 Apr; 8(2):543-54. PubMed ID: 21250746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor and antimetastatic activities of vaccine prepared from cisplatin-resistant lewis lung carcinoma.
    Potebnya GP; Voeykova IM; Lisovenko GS; Cheremshenko NL; Todor IM; Yudina OY; Kovtonyuk OV; Chekhun VF
    Exp Oncol; 2009 Dec; 31(4):226-30. PubMed ID: 20010530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells.
    Tai LH; Zhang J; Scott KJ; de Souza CT; Alkayyal AA; Ananth AA; Sahi S; Adair RA; Mahmoud AB; Sad S; Bell JC; Makrigiannis AP; Melcher AA; Auer RC
    Clin Cancer Res; 2013 Sep; 19(18):5104-15. PubMed ID: 23881927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
    Zeh HJ; Perry-Lalley D; Dudley ME; Rosenberg SA; Yang JC
    J Immunol; 1999 Jan; 162(2):989-94. PubMed ID: 9916724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.